In two public datasets of gene expression and AML patient outcome (TCGA and Beat AML), increased expression of IPO11 was associated with a significant, but modest lower overall survival (Supplemental Fig. S2a). The gene discussed is IPO11; the disease is acute myeloid leukemia.